KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Current Investments (2016 - 2026)

Pacira BioSciences has reported Cash & Current Investments over the past 17 years, most recently at $202.2 million for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 59.04% year-over-year to $202.2 million; the TTM value through Mar 2026 reached $202.2 million, down 59.04%, while the annual FY2025 figure was $238.4 million, 50.8% down from the prior year.
  • Cash & Current Investments for Q1 2026 was $202.2 million at Pacira BioSciences, down from $238.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $493.6 million in Q1 2025 and troughed at $174.0 million in Q1 2023.
  • A 5-year average of $328.8 million and a median of $316.4 million in 2022 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: tumbled 61.52% in 2023 and later skyrocketed 92.96% in 2024.
  • Year by year, Cash & Current Investments stood at $288.7 million in 2022, then fell by 3.49% to $278.6 million in 2023, then skyrocketed by 73.96% to $484.6 million in 2024, then plummeted by 50.8% to $238.4 million in 2025, then decreased by 15.2% to $202.2 million in 2026.
  • Business Quant data shows Cash & Current Investments for PCRX at $202.2 million in Q1 2026, $238.4 million in Q4 2025, and $246.3 million in Q3 2025.